Infectious diseases
Executive Summary
Following cancer, infectious disease is the therapeutic category with the most development activity for biological treatments, a Pharmaceutical Research & Manufacturers of America report states. The "Medicines in Development Biotechnology" 2006 report identifies 50 products in development for infectious diseases and 210 for cancer and related conditions. Autoimmune disorders ranks third with 44 compounds...
You may also be interested in...
China Lays Out Requirements For Biosimilar Extrapolation
In what could be a blow to some aspiring developers eyeing the nascent but growing biosimilars market in China, new rules lay out when extrapolation of approved indications of reference biologics will be allowed, meaning this will not be automatic.
Signs Of Hope But Obstacles Remain For Swiss Device MRA With EU
Without the MRA that allows unimpeded bilateral device trade between the EU and Switzerland, Swiss industry is having to find ways of limiting the damage that newly erected barriers will cause after the MDR comes into force.
Amneal Ready To Go Head-To-Head With Mylan’s Xulane In US
Amneal is set to benefit from 180 days of US exclusivity for its norelgestromin and ethinyl estradiol contraceptive patch product after receiving FDA approval with a competitive generic therapy designation. The generic will be the only competitor to Mylan’s Xulane version.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: